BlackRock Inc. Takes $550.25 Million Position in ICU Medical, Inc. $ICUI

Key Points

• BlackRock acquired 3.75 million ICU Medical shares worth approximately $550.25 million, giving it a 15.02% stake. Institutional investors collectively own 96.10% of the company.
• ICU Medical exceeded quarterly expectations, reporting $2.37 EPS versus a $1.91 estimate and $547.88 million in revenue. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $192.80.
• Several company insiders sold shares recently, including transactions totaling approximately $3.09 million over the past 90 days; insiders own 2.10% of the stock.

BlackRock Inc. acquired a new position in shares of ICU Medical, Inc. (NASDAQ:ICUI - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 3,753,409 shares of the medical instruments supplier's stock, valued at approximately $550,250,000. BlackRock Inc. owned about 15.02% of ICU Medical at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of ICUI. Maryland State Retirement & Pension System grew its holdings in ICU Medical by 2.0% during the fourth quarter. Maryland State Retirement & Pension System now owns 3,619 shares of the medical instruments supplier's stock worth $516,000 after purchasing an additional 70 shares during the period. California Public Employees Retirement System increased its holdings in shares of ICU Medical by 0.3% during the 1st quarter. California Public Employees Retirement System now owns 30,461 shares of the medical instruments supplier's stock worth $3,934,000 after acquiring an additional 90 shares during the last quarter. Oregon Public Employees Retirement Fund increased its holdings in shares of ICU Medical by 1.8% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 5,631 shares of the medical instruments supplier's stock worth $803,000 after acquiring an additional 100 shares during the last quarter. Smartleaf Asset Management LLC raised its stake in ICU Medical by 11.6% in the 2nd quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier's stock valued at $128,000 after acquiring an additional 101 shares during the period. Finally, Lido Advisors LLC lifted its holdings in ICU Medical by 4.5% during the 4th quarter. Lido Advisors LLC now owns 2,479 shares of the medical instruments supplier's stock valued at $354,000 after purchasing an additional 106 shares during the last quarter. 96.10% of the stock is owned by institutional investors.

ICU Medical Stock Performance

Shares of NASDAQ:ICUI opened at $182.55 on Tuesday. ICU Medical, Inc. has a 12-month low of $112.50 and a 12-month high of $192.85. The company's 50 day moving average price is $161.62 and its two-hundred day moving average price is $143.30. The firm has a market cap of $4.56 billion, a PE ratio of 154.70, a PEG ratio of 2.31 and a beta of 0.74. The company has a quick ratio of 1.21, a current ratio of 2.43 and a debt-to-equity ratio of 0.56.

ICU Medical (NASDAQ:ICUI - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.46. The business had revenue of $547.88 million during the quarter, compared to analysts' expectations of $533.44 million. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%.The firm's revenue for the quarter was up .5% compared to the same quarter last year. During the same period in the previous year, the company posted $2.10 earnings per share. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Equities research analysts predict that ICU Medical, Inc. will post 7.19 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on ICUI shares. Zacks Research downgraded shares of ICU Medical from a "strong-buy" rating to a "hold" rating in a report on Tuesday, July 28th. Weiss Ratings upgraded shares of ICU Medical from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday, July 23rd. Needham & Company LLC lifted their target price on shares of ICU Medical from $165.00 to $187.00 and gave the stock a "buy" rating in a report on Friday, August 7th. Jefferies Financial Group upgraded shares of ICU Medical to a "strong-buy" rating in a research note on Thursday, May 7th. Finally, KeyCorp raised their price objective on shares of ICU Medical from $164.00 to $182.00 and gave the stock an "overweight" rating in a research report on Tuesday, July 21st. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, ICU Medical currently has an average rating of "Moderate Buy" and an average target price of $192.80.

Insider Buying and Selling

In other news, VP Daniel Woolson sold 5,417 shares of the stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $181.33, for a total transaction of $982,264.61. Following the sale, the vice president directly owned 17,062 shares of the company's stock, valued at approximately $3,093,852.46. This represents a 24.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Ben Sousa sold 2,250 shares of the firm's stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $178.32, for a total value of $401,220.00. Following the completion of the transaction, the insider owned 3,076 shares in the company, valued at $548,512.32. The trade was a 42.25% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 16,974 shares of company stock valued at $3,085,844. Company insiders own 2.10% of the company's stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source